Indaptus Therapeutics Inc (INDP)

$3.54 -0.07 (-1.94%)
Market Cap 8.10M
Revenue (ttm) 0.00
Net Income (ttm) -20.85M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 79,800
Avg Vol 52,860
Day's Range N/A - N/A
Shares Out 2.24M
Stochastic %K 87%
Beta 0.97
Analysts Strong Sell
Price Target $10.00

Company Profile

Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The com...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 427 2727
Address:
Three Columbus Circle, 15th Floor, New York, United States
RocroBio
RocroBio Apr. 19 at 5:21 PM
$CRBU $INDP $IRWD
1 · Reply
daybaron
daybaron Apr. 17 at 8:00 PM
$INDP very nice week, hope we can keep it going along with some news
1 · Reply
daybaron
daybaron Apr. 17 at 7:56 PM
$INDP jeez let's get to four before we worry about 5-6
0 · Reply
okjasa
okjasa Apr. 17 at 4:18 PM
$INDP Resistance zone $5.50–6.00
0 · Reply
RA__
RA__ Apr. 17 at 4:15 PM
$INDP what a great scam, literally going up on air. i'd like to see a repeat of NBY.
0 · Reply
TruthTooPower
TruthTooPower Apr. 16 at 6:33 PM
$INDP!!! 🤓🤓🤓🤓🤓 🙌🙌🙌🙌🙌
0 · Reply
IBBullish
IBBullish Apr. 16 at 1:39 AM
$INDP scam
0 · Reply
STACKD0E
STACKD0E Apr. 15 at 1:49 PM
$INDP $CRBU $IRWD
0 · Reply
RA__
RA__ Apr. 14 at 6:36 PM
$INDP david lazar stock, he converted his shares and now starting to walk up. when he converted his shares on nby it ran from 80 cents to 20 bucks. i hope same thing can happen here again
2 · Reply
TruthTooPower
TruthTooPower Apr. 14 at 2:22 PM
$INDP!!! 🤓🤓🤓🤓🤓🤓🤓🤓🤓 All New Executive Board!!!
0 · Reply
Latest News on INDP
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Dec 29, 2025, 7:00 AM EST - 4 months ago

Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Nov 17, 2025, 8:00 AM EST - 5 months ago

Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection & Cell Source Summit

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 8:30 AM EST - 5 months ago

Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Provides Clinical Update

Sep 4, 2025, 4:01 PM EDT - 8 months ago

Indaptus Therapeutics Provides Clinical Update

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Sep 2, 2025, 4:05 PM EDT - 8 months ago

Indaptus Therapeutics to Present at the H.C. Wainwright 27ᵗʰ Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 8:00 AM EDT - 9 months ago

Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Jul 1, 2025, 8:14 AM EDT - 10 months ago

Indaptus Therapeutics, Inc. Announces Additional Sale of $3.4 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Announces Reverse Stock Split

Jun 25, 2025, 7:00 AM EDT - 10 months ago

Indaptus Therapeutics Announces Reverse Stock Split

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Jun 13, 2025, 8:00 AM EDT - 11 months ago

Indaptus Therapeutics, Inc. Announces Sale of $2.3 Million in Private Placement of Convertible Notes and Warrants

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Indaptus Therapeutics Doses First Patient in Phase 1b/2 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

May 8, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Mar 13, 2025, 7:30 AM EDT - 1 year ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Mar 12, 2025, 4:15 PM EDT - 1 year ago

Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Mar 4, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Feb 25, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Feb 5, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Jan 8, 2025, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Nov 22, 2024, 8:36 AM EST - 1 year ago

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Nov 11, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Nov 7, 2024, 8:00 AM EST - 1 year ago

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Oct 23, 2024, 8:00 AM EDT - 1 year ago

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Apr 11, 2024, 7:30 AM EDT - 2 years ago

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:30 AM EDT - 2 years ago

Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Mar 13, 2024, 7:30 AM EDT - 2 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Mar 4, 2024, 7:30 AM EST - 2 years ago

Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

Feb 8, 2024, 8:00 AM EST - 2 years ago

Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Jan 4, 2024, 8:00 AM EST - 2 years ago

European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 4:01 PM EST - 2 years ago

Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Oct 31, 2023, 9:01 AM EDT - 2 years ago

Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Sep 26, 2023, 8:00 AM EDT - 2 years ago

Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Aug 10, 2023, 8:45 AM EDT - 2 years ago

Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Aug 7, 2023, 8:00 AM EDT - 2 years ago

Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

May 11, 2023, 7:00 AM EDT - 3 years ago

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

May 9, 2023, 8:00 AM EDT - 3 years ago

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

May 1, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

Apr 20, 2023, 4:05 PM EDT - 3 years ago

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 9:28 AM EDT - 3 years ago

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Apr 19, 2023, 8:05 AM EDT - 3 years ago

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics to Present at the Investor Summit Conference

Mar 22, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics to Present at the Investor Summit Conference

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Mar 17, 2023, 8:00 AM EDT - 3 years ago

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Mar 15, 2023, 8:05 AM EDT - 3 years ago

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 13, 2023, 8:05 AM EDT - 3 years ago

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Mar 7, 2023, 8:05 AM EST - 3 years ago

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

RocroBio
RocroBio Apr. 19 at 5:21 PM
$CRBU $INDP $IRWD
1 · Reply
daybaron
daybaron Apr. 17 at 8:00 PM
$INDP very nice week, hope we can keep it going along with some news
1 · Reply
daybaron
daybaron Apr. 17 at 7:56 PM
$INDP jeez let's get to four before we worry about 5-6
0 · Reply
okjasa
okjasa Apr. 17 at 4:18 PM
$INDP Resistance zone $5.50–6.00
0 · Reply
RA__
RA__ Apr. 17 at 4:15 PM
$INDP what a great scam, literally going up on air. i'd like to see a repeat of NBY.
0 · Reply
TruthTooPower
TruthTooPower Apr. 16 at 6:33 PM
$INDP!!! 🤓🤓🤓🤓🤓 🙌🙌🙌🙌🙌
0 · Reply
IBBullish
IBBullish Apr. 16 at 1:39 AM
$INDP scam
0 · Reply
STACKD0E
STACKD0E Apr. 15 at 1:49 PM
$INDP $CRBU $IRWD
0 · Reply
RA__
RA__ Apr. 14 at 6:36 PM
$INDP david lazar stock, he converted his shares and now starting to walk up. when he converted his shares on nby it ran from 80 cents to 20 bucks. i hope same thing can happen here again
2 · Reply
TruthTooPower
TruthTooPower Apr. 14 at 2:22 PM
$INDP!!! 🤓🤓🤓🤓🤓🤓🤓🤓🤓 All New Executive Board!!!
0 · Reply
TruthTooPower
TruthTooPower Apr. 14 at 2:22 PM
$INDP!!! !!!!!!!!MICRO FLOAT BABY!!!!!!! 🙌 🙌 🙌
0 · Reply
TruthTooPower
TruthTooPower Apr. 14 at 1:57 PM
$INDP!!! !!!!!!!!DOUBLE DIGITS!!!!!!!! 🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓🤓
0 · Reply
UnicornPicks
UnicornPicks Apr. 14 at 1:45 PM
$KEEL $INDP $CHPT
0 · Reply
TruthTooPower
TruthTooPower Apr. 13 at 2:15 PM
$INDP!!!! HELL YEAH!!! 🙌 🙌 🙌 Get Ready To RRUUUUMMMMBBBLLLEEE!! It's About Time To Rock!!!!
0 · Reply
daybaron
daybaron Apr. 10 at 6:56 PM
$INDP it seems that this wants to go higher, but what do i know
0 · Reply
TruthTooPower
TruthTooPower Apr. 10 at 3:19 PM
$INDP!!! !!!!!!!!!!!🤓🤓🤓🤓!!!!!!!!!!! Hell Yeah!!! 🙌 🙌 🙌
0 · Reply
TruthTooPower
TruthTooPower Apr. 9 at 4:04 PM
$INDP!!! This Valuation Is 50% Of What It Should Be!!!
0 · Reply
TruthTooPower
TruthTooPower Apr. 9 at 2:13 PM
$INDP!!! Come On Guys!!! Walk This Way!!!!!!!
0 · Reply
VENDETTAV
VENDETTAV Apr. 9 at 8:34 AM
$INHD $PMAX $UCAR $INDP Inhd has the looks
0 · Reply
SPARTANVI
SPARTANVI Apr. 9 at 8:31 AM
$INHD HK like $PMAX went hard yesterday bottom play Be early on these $UCAR $INDP
0 · Reply
TruthTooPower
TruthTooPower Apr. 8 at 5:56 PM
$INDP!!! To Da Moon!!!!!!!!!!!!!!!!!!
0 · Reply
TruthTooPower
TruthTooPower Apr. 8 at 4:53 PM
$INDP!!! !!!!!!!!!!!!!!🤓!!!!!!!!!!!!!!!!
0 · Reply